]>
IRCT2017050433810N1 IRCT 2017-05-28 Vice Chancellor for Research, Mashhad University of Medical Sciences The effects of curcumin on Attention-Deficit/Hyperactivity Disorder (ADHD) patients A clinical trial to compare the effects of curcumin with placebo on Attention-Deficit/Hyperactivity Disorder (ADHD) patients undergoing Ritalin treatment 2017-05-22 anticipated 70 Complete https://irct.ir/trial/25989 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 2 Attention-Deficit/Hyperactivity Disorder (ADHD). Intervention 1: Control group: Children and teenagers with Attention-Deficit/Hyperactivity Disorder (ADHD) undergoing Ritalin treatment (0.1-3 mg) received 80 mg of placebo (similar components of curcumin capsules) twice a day. Intervention 2: Intervention group: Children and teenagers with Attention-Deficit/Hyperactivity Disorder (ADHD) undergoing Ritalin treatment (0.1-3 mg) received 80 mg of curcumin (Sina Drug) twice a day.
public Marzea Ranghian
Ghoreyshi building, Daneshgah street
Mashhad Iran (Islamic Republic of) +98 51 3728 1401 rangianm931@mums.ac.ir Mashhad University of Medical Sciences scientific Marzea Ranghian
Ghoreyshi building, Daneshgah street
Mashhad Iran (Islamic Republic of) +98 51 3711 2701 rangianm931@mums.ac.ir Mashhad University of Medical Sciences Iran (Islamic Republic of) Inclusion criteria: Aged between 7 and 15 years; diagnosis Attention-Deficit/Hyperactivity Disorder (ADHD) based on DSM-V-TR criteria; lack of mental retardation (MR), epilepsy, pervasive developmental disorder, schizophrenia, mania episode, anxiety disorders, bipolar disorder, special ability and learning disorders, and hyperactivity disorder due to organic brain syndrome (OBS) or drug reactions. Exclusion criteria: Liver and renal failure; thyroid disorder; allergy to curcumin; chronic inflammatory diseases; use of anti-inflammatory and antioxidant drugs. 7 years 15 years Both F90.0 Disturbance of activity and attention Treatment - Drugs Treatment - Drugs Control group: Children and teenagers with Attention-Deficit/Hyperactivity Disorder (ADHD) undergoing Ritalin treatment (0.1-3 mg) received 80 mg of placebo (similar components of curcumin capsules) twice a day. Intervention group: Children and teenagers with Attention-Deficit/Hyperactivity Disorder (ADHD) undergoing Ritalin treatment (0.1-3 mg) received 80 mg of curcumin (Sina Drug) twice a day. Evaluation the effectiveness of clinical outcomes including learn, impulsivity, anxiety, hyperactivity and conduct disorder (CD) score. Timepoint: before, 4 and 8 weeks after intervention. Method of measurement: Base on questionnaire. Vice Chancellor for Research, Mashhad University of Medical Sciences Approved 2015-11-18 Ethics Committee of Mashhad University of Medical Sciences Vice Chancellor for Research, Mashhad University of Medical Sciences, Ghoreishi building, Daneshgah Street Mashhad Iran (Islamic Republic of)